TransMedics Group (NASDAQ:TMDX) Given New $77.00 Price Target at UBS Group

TransMedics Group (NASDAQ:TMDX) had its target price dropped by UBS Group from $80.00 to $77.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group’s price target would suggest a potential upside of 0.67% from the stock’s current price.

A number of other analysts also recently issued reports on TMDX. Weiss Ratings downgraded TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. Zacks Research lowered TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday. Finally, Needham & Company LLC dropped their price target on shares of TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research note on Monday. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $124.18.

TransMedics Group Stock Performance

NASDAQ TMDX traded down $4.26 during trading hours on Wednesday, reaching $76.49. 2,950,172 shares of the company were exchanged, compared to its average volume of 1,089,457. The stock has a market capitalization of $2.64 billion, a P/E ratio of 17.38 and a beta of 1.90. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group has a 1 year low of $60.10 and a 1 year high of $156.00. The business’s 50 day simple moving average is $73.01 and its 200-day simple moving average is $99.72.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter in the previous year, the firm earned $0.92 earnings per share. The firm’s revenue was up 20.7% compared to the same quarter last year. On average, equities research analysts expect that TransMedics Group will post 1.88 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its position in shares of TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after purchasing an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after buying an additional 868 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after buying an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. grew its position in TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after acquiring an additional 938 shares in the last quarter. Finally, M&T Bank Corp bought a new position in TransMedics Group in the second quarter valued at $209,000. 99.67% of the stock is currently owned by institutional investors.

More TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Second-quarter revenue increased 20.7% year over year to approximately $189.95 million, exceeding the $184 million consensus estimate. TransMedics also raised its fiscal 2026 revenue outlook to $737 million–$757 million, above analysts’ $733.6 million estimate. TransMedics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Piper Sandler reaffirmed its “overweight” rating, although it reduced its price target to $100 from $120. The revised target still implies substantial potential upside from recent trading levels. Piper Sandler Rating Update
• Neutral Sentiment: Management’s second-quarter earnings call highlighted continued demand and growth, while investors focused on the company’s cost structure, operating investments and the path for margins. TransMedics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Adjusted earnings were $0.44 per share, below the $0.50 consensus estimate and down from $0.92 a year earlier. Operating profit and net income also fell, while sharply higher operating expenses pressured margins. TransMedics Q2 Earnings Lag Estimates
• Negative Sentiment: Cash-flow performance weakened, with operating cash flow of approximately $17.3 million, adding to concerns that investments and expenses may be outpacing near-term profit growth. TransMedics Q2 2026 Earnings Overview
• Negative Sentiment: Needham issued a pessimistic forecast, while Rosen Law Firm announced an investigation into potential fiduciary-duty breaches by TransMedics’ directors and officers. The investigation is an allegation, not a finding of wrongdoing, but it adds headline and legal risk. Needham Forecast Rosen Law Firm Investigation

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.